PROSTATENOW™ is a germline test for people who have been diagnosed with prostate cancer or have a family history of prostate cancer or other hereditary cancer disorders.
This test can aid in predicting risk levels associated with cancer progression or disease development, as well as in identifying potential targeted therapy options.
PROSTATENOW™ was developed in collaboration with NorthShore University HealthSystem and is the only commercially available germline panel that incorporates three screening methods (family history, rare pathogenic mutations (RPMs), and genetic risk score (GRS)) for a comprehensive inherited prostate cancer risk assessment.